Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGM - Delayed Quote USD

Denali Capital Acquisition Corp. (DECAU)

Compare
11.84
0.00
(0.00%)
At close: February 21 at 4:00:00 PM EST
Advanced Chart
Loading Chart for DECAU
  • Previous Close 11.84
  • Open 11.84
  • Bid --
  • Ask --
  • Day's Range 11.84 - 11.84
  • 52 Week Range 5.26 - 12.20
  • Volume 15
  • Avg. Volume 232
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 0.34
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Denali Capital Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. It intends to complete a business combination with companies primarily operating in the technology, consumer services, and hospitality sectors. The company was incorporated in 2022 and is based in New York, New York.

--

Full Time Employees

December 31

Fiscal Year Ends

Financial Services

Sector

Shell Companies

Industry

More about Denali Capital Acquisition Corp.

Recent News: DECAU

View More

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
GlobeNewswire yesterday
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali
GlobeNewswire 4 months ago
Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary
GlobeNewswire 4 months ago
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion
GlobeNewswire 4 months ago
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion
GlobeNewswire 6 months ago

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination
GlobeNewswire 6 months ago

Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination
GlobeNewswire 7 months ago
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination
GlobeNewswire 8 months ago

Correction: Denali Capital Acquisition Corp. and Longevity Biomedical, Inc. Mutually Agreed to Terminate the Business Combination
GlobeNewswire 8 months ago

Top Midday Gainers
PREMIUM
MT Newswires 8 months ago

Denali Capital Acquisition Corp. and Longevity Biomedical, Inc. Mutually Agreed to Terminate the Business Combination
GlobeNewswire 8 months ago
View More

Performance Overview: DECAU

Trailing total returns as of 3/12/2025, which may include dividends or other distributions. Benchmark is S&P 500 .

YTD Return

DECAU
0.42%
S&P 500
4.80%

1-Year Return

DECAU
89.74%
S&P 500
8.19%

3-Year Return

DECAU
18.05%
S&P 500
33.18%

5-Year Return

DECAU
18.05%
S&P 500
125.72%

Compare To: DECAU

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

DECAU
Denali Capital Acquisition Corp.
11.84
0.00%
Mkt Cap -
Industry Shell Companies
SKGR
SK Growth Opportunities Corporation
11.70
+0.17%
Mkt Cap 175.184M
Industry Shell Companies

Statistics: DECAU

View More

Valuation Measures

Annual
As of

  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -1.18%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    1.23M

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    14.29k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -432.7k

View More

Company Insights: DECAU

People Also Watch

DECA Denali Capital Acquisition Corp.
12.02
0.00%
 
AIMAU Aimfinity Investment Corp. I
12.00
0.00%
 
MSSAU Metal Sky Star Acquisition Corporation
11.89
+0.76%
 
EMCGU Embrace Change Acquisition Corp.
12.11
+0.98%
 
CLRCU ClimateRock
12.39
0.00%
 
FTIIU FutureTech II Acquisition Corp.
11.01
0.00%
 
FTII FutureTech II Acquisition Corp.
11.55
-1.95%
 
CLRC ClimateRock
11.92
0.00%
 
RENEU Cartesian Growth Corporation II
11.69
0.00%
 
IVCAU Investcorp AI Acquisition Corp.
11.86
-1.08%
 
EGRVF Evergreen Corporation
12.09
0.00%
 
CFSB CFSB Bancorp, Inc.
7.55
-0.13%
 
BYNO byNordic Acquisition Corporation
11.45
+0.44%
 
GATEU Marblegate Acquisition Corp.
10.93
0.00%
 
DAVEW Dave Inc.
0.1711
+6.87%
 
DECAW Denali Capital Acquisition Corp.
0.0372
-25.30%